靶向ACE2受体的纳米药物:肺癌治疗的新途径

Dillon Sivalingam, Moganavelli Singh
{"title":"靶向ACE2受体的纳米药物:肺癌治疗的新途径","authors":"Dillon Sivalingam, Moganavelli Singh","doi":"10.24294/ti.v7.i1.1838","DOIUrl":null,"url":null,"abstract":"The angiotensin-converting enzyme 2 (ACE2) receptor gained prominence in 2020, having been identified as a prime receptor for entry of the novel coronavirus COVID-19, which has led to the current global pandemic. Many studies have reported that lung cancer patients have a higher risk of contracting COVID-19 due to the up-regulated expression of ACE2 in lung cancer cells. Lung cancer is a heterogeneous disease and the most frequently occurring cancer globally. It is more prevalent in men than in women and accounts for an estimated 40% of cancer cases. Over the years, many studies have reported on the ACE2 expression in lung cancer. Conventional methods currently available for the detection and treatment of lung cancer face numerous challenges. Nanomedicine has risen to many challenges facing cancer therapy and drug delivery. With the array of nano delivery systems available, nanomedicine can be used to develop alternative methods to help overcome these challenges and improve the therapeutic efficiency in cancer therapy. Hence, this review focuses on lung cancer, the ACE2 receptor, and the use of nanomedicine in formulating a novel targeted cancer treatment strategy directed at the ACE2 receptor. This may serve as a stepping stone for exploring further targeting strategies and therapies.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy\",\"authors\":\"Dillon Sivalingam, Moganavelli Singh\",\"doi\":\"10.24294/ti.v7.i1.1838\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The angiotensin-converting enzyme 2 (ACE2) receptor gained prominence in 2020, having been identified as a prime receptor for entry of the novel coronavirus COVID-19, which has led to the current global pandemic. Many studies have reported that lung cancer patients have a higher risk of contracting COVID-19 due to the up-regulated expression of ACE2 in lung cancer cells. Lung cancer is a heterogeneous disease and the most frequently occurring cancer globally. It is more prevalent in men than in women and accounts for an estimated 40% of cancer cases. Over the years, many studies have reported on the ACE2 expression in lung cancer. Conventional methods currently available for the detection and treatment of lung cancer face numerous challenges. Nanomedicine has risen to many challenges facing cancer therapy and drug delivery. With the array of nano delivery systems available, nanomedicine can be used to develop alternative methods to help overcome these challenges and improve the therapeutic efficiency in cancer therapy. Hence, this review focuses on lung cancer, the ACE2 receptor, and the use of nanomedicine in formulating a novel targeted cancer treatment strategy directed at the ACE2 receptor. This may serve as a stepping stone for exploring further targeting strategies and therapies.\",\"PeriodicalId\":401129,\"journal\":{\"name\":\"Trends in Immunotherapy\",\"volume\":\"14 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24294/ti.v7.i1.1838\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24294/ti.v7.i1.1838","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

血管紧张素转换酶2 (ACE2)受体在2020年获得了关注,已被确定为导致当前全球大流行的新型冠状病毒COVID-19进入的主要受体。许多研究报道,由于肺癌细胞中ACE2表达上调,肺癌患者感染新冠病毒的风险更高。肺癌是一种异质性疾病,是全球最常见的癌症。它在男性中比在女性中更为普遍,估计占癌症病例的40%。多年来,许多研究报道了ACE2在肺癌中的表达。目前用于检测和治疗肺癌的传统方法面临许多挑战。纳米医学已成为癌症治疗和给药面临的诸多挑战。随着纳米递送系统阵列的出现,纳米医学可以用来开发替代方法来帮助克服这些挑战,提高癌症治疗的治疗效率。因此,本文将重点介绍肺癌、ACE2受体以及纳米药物在制定针对ACE2受体的新型靶向癌症治疗策略中的应用。这可能是探索进一步靶向策略和治疗的垫脚石。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy
The angiotensin-converting enzyme 2 (ACE2) receptor gained prominence in 2020, having been identified as a prime receptor for entry of the novel coronavirus COVID-19, which has led to the current global pandemic. Many studies have reported that lung cancer patients have a higher risk of contracting COVID-19 due to the up-regulated expression of ACE2 in lung cancer cells. Lung cancer is a heterogeneous disease and the most frequently occurring cancer globally. It is more prevalent in men than in women and accounts for an estimated 40% of cancer cases. Over the years, many studies have reported on the ACE2 expression in lung cancer. Conventional methods currently available for the detection and treatment of lung cancer face numerous challenges. Nanomedicine has risen to many challenges facing cancer therapy and drug delivery. With the array of nano delivery systems available, nanomedicine can be used to develop alternative methods to help overcome these challenges and improve the therapeutic efficiency in cancer therapy. Hence, this review focuses on lung cancer, the ACE2 receptor, and the use of nanomedicine in formulating a novel targeted cancer treatment strategy directed at the ACE2 receptor. This may serve as a stepping stone for exploring further targeting strategies and therapies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信